The SBTF is a 501(c)3 non-profit, public charitable organization based in Atlanta, GA. We fund scientific research and investigator-initiated clinical trials focused on finding a cure for brain tumors. Since 2005, the SBTF has awarded more than $2.3M in research grants. Our Research Grant program provides seed money and stimulates brain tumor research. At the SBTF we:

  • seek out the best science using a Medical Advisory Board to review all applications
  • award the project which has the best chance of leading to a cure
  • can direct 100% of your dollars toward the best science in the Southeast

SBTF grant funds are not a source of continuing support but are considered seed money for the development of research and clinical trials which will advance technologies and treatments for brain tumor patients.  We seek brain tumor research which focuses on curative and clinical applications.  Grant funds may be used for start-up projects or supplementary funding.  Funds may not be used to support indirect costs or staff expense.  SBTF Grants will be issued for up to a one-year period.

Grant Submission and Process

Our next grant cycle is currently slated for May 1, 2017 – April 30, 2018. Our Research Grant Submission Guidelines and Instructions for the 2017 granting cycle will be made available in December of 2017.

Proposals received by the deadline, and meeting submission criteria, will be peer reviewed by the SBTF Medical Advisory Board with recommendations presented to the SBTF Board of Directors. Grant Award notifications are currently slated for April 21, 2017.

REQUEST INFORMATION

 


Research Grants Awarded

We are pleased to provide a list of research grant projects which have been funded by the SBTF.   Funding of these research projects has been made possible through the generosity of our constituents and the support of Race for Research participants.

Please feel free to contact us with any questions you may have regarding our research grants.  We can be reached via email (grants@sbtf.org or gshaffer@sbtf.org) or via telephone at 786-505-SBTF (7283).

2016 Grants: $150,000

Awarded June 2016

Yiping He, MD, Ph.D., Duke University, Preston Robert Tisch Brain Tumor Center, Durham, NC
Exploiting MTAP for more effective treatment of glioblastoma with temozolomide

Eric M. Thompson, MD, Duke University Medical Center, Durham, NC
Optimizing the Convection Enhanced Delivery of Targeted Agents for Midline gliomas

Erwin G. Van Meir, Ph.D., Emory University, Atlanta, GA
Investigating the role of N-cadherin in the therapeutic resistance of Glioblastoma

 

2015 Grants: $125,000

Awarded May 2015

Hai Ye, MD, Ph.D., Duke University Medical Center, Durham, NC
Developing a clinically relevant animal model and investigating therapeutics for targeting PPM1D mutations in brainstem glioma.

Keqiang Ye, Ph.D., Emory University, Atlanta, GA.
PIKE-A/Cdk4 Complex is a Novel Drug Target for Treating Glioblastoma

 

2014 Grants: $200,000

Awarded May 2014

Hui-Kuo Shu, Emory University, Atlanta, GA
Therapeutic Targeting of Id1 in Glioblastomas

Tracy-Ann Read, Phd, Emory School of Medicine, Atlanta, GA
Characterizing the role of second hit genes in SNF5 deficient tumors

Matthias Gromeier, MD, Duke University Medical Center, Durham, NC
Oncolytic Polio Immunotherapy for Glioblastoma

Chin Chiang. Ph.D., Vanderbilt University Medical Center, Nashville, TN
Redox Function in Medulloblastoma

Kevin Cassady, MD, University of Alabama, Birmingham, Birmingham, AL
The oHSV-mediated immune response: engineering log-term Anti-GBM Immunity”

 

 2013 Grants: $200,000

Awarded May 2014, Award Ceremony September 2014

 Kevin Cassady, MD, University of Alabama, Birmingham
The oHSV-mediated Immune Response:Â  Engineering Long-Term Anti-GBM Immunity

Chin Chiang, Ph.D. Vanderbilt University Medical Center
“Redox Function in Medulloblastoma”

Matthias Gromeier, MD, Duke University Medical Center
Oncolytic Polio Immunotherapy for Glioblastoma”

Tracy-Ann Read, Ph.D. Emory University School of Medicine
Characterizing the role of second-hit genes in SNF5 deficient tumors

Hui-Kuo G. Shu, MD., Ph.D.  Emory University
Therapeutic Targeting of Id1 in Glioblastomas

 

2012 Grants: $175,000

Awarded April 2013, Award ceremony September 2013

Prakash Chinnaiyan, MD, H. Lee Moffitt Cancer Center and Research Institute
Determining Biologic Consequence of Cysteine Catabolism

Lawrence S. Lamb, Jr., Ph.D., Wallace Tumor Institute, University of Alabama at Birmingham
Temozolomide-resistant gene-modified yS T cells for High GradeGliomas

Renee Read, Ph.D., Emory University School of Medicine – Phil Jory Research Award Recipient
Revealing a role for Stk17A in glioblastoma invasion and proliferation

 

2011 Grants: $245,397

Awarded April 2012

Satish K. Chitneni, Ph.D., Duke University Medical Center
PET Imaging iDH1-R1324H in Glioma

Jialiang Wang, Ph.D., Vanderbilt University
GBM Stem Cell Treatment

Erwin G. Van Meir, Ph.D., Emory University
BA1 Tumor Supressor in Medulloblastoma

Etty (Tika) Benveniste, Ph.D., University of Alabama atBirmingham
Defining the Role of Nf-kB in Promoting STAT3 Activation in Malignant Gliomas

 

2010 Grants: $225,000

Award Ceremony conducted April 15, 2011

Craig Castellino, MD, PhD, Emory University
“Inhibition of WIP1-mediated metastasis in medulloblastoma”

Laura Johnson, PhD, Duke University
“Reversing CD28:B7 ligand/receptor superfamily-mediated immune deficits in cytomegalovirus infected GBM patients”

Hai Yan, MD, Duke University
“The role of D-2-hydroxyglutarate in glioma pathology, diagnosis and therapy”

Tracy-Ann Read, PhD, Emory University
“Identification and Characterization of the Cell of Origin for AtypicalTeratoid/Rhabdoid Tumors (AT/RTS)”

 

2009 Grants: $275,000

Award Ceremony conducted March 2010

Dr. Van Meir, PhD, Emory University

“Therapeutic Modulation of the Methyl-CpG-Binding Domain Protein 2 (MBD2) in Glioma”

Dr. Chandramohan, MD. PhD., Duke University

“D2C7-NZ-1:  A Novel Recombinant Trispecific Single-Chain Immunotoxin for the Treatment of Malignant Glioma”

Dr. Laura Johnson, MD. PhD., Duke University

“Research Project on EGFRvIII Chimeric Antigen Receptor-Modified T Cell Immunotherapy of Glioblastoma”

Dr. Jeffrey Olson, MD, Emory University

“Glioblastoma Stem Cell Resistance to Proteasome Inhibition: Assessment of Mechanisms”

 

2008 Grants: $300,000

Awarded, May 17, 2009

 Dr. Nozell, MD, University of Alabama
“Role of NF-KB in promoting tumorigenicity”

Dr. Gromeier, MD, Duke University
“Oncolytic virotheraply for metastic medullablastoma”

Dr. Mitchell, MD, Duke University
“Enhancing immunity to malignant glioma during hematopoieticrecvery from lymphodepletive temozolomide”

Dr. Reya, MD, Duke University
“Creating a new mouse model for large cell anaplasticmedullablastoma”

Dr. Costas G. Hadjipanayis, MD. PhD, Emory University
“EGFRVIII antibody conjugated magnetic nanoparticles for targeted imaging and therapy”

 

2007 Grants: $270,000

Awarded, January 30, 2008

Dr. Yiting Cao, MD, Duke University
For his work with Dr. Jeremy Rich and the Erythropoietin Regulation of Brain Tumor Stem Cells.

Dr. Charlie Hao, MD, Emory University
For his work of Combination Treatment of GBM with TRAIL and Hsp90 Inhibitors.

Dr. Erwin Van Meir, PhD, Emory University
For work on a novel anti-angiogenic function for the p14ARF tumor suppressor in Glioma.

 

2006 Grants: $210,432

Dr. Michael W. Graner, PhD., Duke University
Heat Shock Protein Vaccines as Immunotherapy against Malignant Glioma.

Dr. Erwin Van Meir, PhD, Emory University
Pre-clinical development of a Novel Small Molecule HIF-1 Inhibitor for the Therapy of Malignant Brain Tumors.

Dr. Matthias Gromeier, MD, Duke University
Evaluation of Oncolytic Poliovirus Recombinants in a Syngeneic Rodent Glioma Model

 

2005 Grants: $110,000

Dr. Hai Yan, PhD, Duke University
Characterization of OTX2 as a Novel Therapeutic Targer and Prognostic Marker Medulloblastoma

Dr. Chunhai (Charlie) Hao, MD, PhD, Winship Cancer Institute – Emory University
Development of TRAIL-based Therapies for Glioblastomas

Anita Hjelmeland, PhD, Duke University
PTEN Loss in Gliomas Promotes Pro-Tumorigenic Responses to Transforming Growth Factor Beta